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ABSTRACTSBackground: The new national guideline from NHS improvement was to
notify relevant team of known cancer patient being acutely admitted to
hospitals providing acute oncological service. A new uro-oncology alert
system by text and e-mail was set up at our District General Hospital
accordingly.
Aim: To assess the time delay of notiﬁcation of acute admission. To assess
the quality of referrals and outcomes for urological cancers through the
system
Methods: Prospective assessment of the 53 referrals through the alert
system from October 2011 to January 2012.
Results: Of the 53, 32 patients had same day notiﬁcation. Signiﬁcant delay
of more than 72 hours was in 3 patients. 19 of these were for urological
cancer related admissions while 6 were for non urological cancers and the
rest were for non cancer related events. 5 patients had urgent input in their
care that has resulted in better outcomes.
Conclusion: About 10% of patients had averted a signiﬁcant
adverse outcome because of the alert. Delay in notiﬁcation and false
notiﬁcations are the problems of initial service setup and should be
corrected at the patient inclusion level. Longer numbers are needed to
ascertain if the alert system would bring about signiﬁcantly better
outcomes.
1150: CAN RENAL TUMOUR CHARACTERISTICS HELP US PREDICT TIME
TO TUMOUR RECURRENCE?
Tsong Kwong, Dan Magrill, Nick Ting, Samuel Ling, Hwee Jeon,
Cathy Corbishley, Uday Patel, Ayres Ben, Pieter Le Roux,
Christopher Anderson. St Georges Hospital, London, UK.
Aims: The incidence of renal carcinoma is increasing with more ne-
phrectomies being performed. It has a high recurrence rate, with 20-30%
developing metastases after nephrectomy; however information about
time to recurrence is often lacking. The aim of this study was determine
timescales of recurrence based on tumour characteristics.
Methods: Using our prospectively compiled database on radical ne-
phrectomies, our analysis concentrated on the incidence and time to
recurrence, and also tumour characteristics such as stage and grade.
Results: We had complete data for 205 patients.
For pT1 cancers (n ¼ 60), the median time to recurrence was 38.5 months,
for pT2 (n¼41) 24 months and for pT3 (n¼99) 13 months (p ¼ 0.09). For
low grade tumours (G1-2, n¼ 98), the median recurrence time was 42
months and for high grade tumours (G3-4, n ¼ 106), it was 11 months,
which was statistically signiﬁcant (p¼0.004).
Conclusions: This data shows that tumours with higher grade and stage
are likely to recur earlier, and that higher grade tumours recur more often.
This information should enable clinicians to counsel patients more accu-
rately, and could be implemented into local diagnostic and follow-up
protocols.
1153: DO INTRAVENOUS UROGRAMS STILL HAVE A ROLE IN INVESTI-
GATING RENAL COLIC? A PROSPECTIVE AUDIT OF PRACTICE IN A DGH
Miranda Lewis, Eleanor Winstanley, Michael Shenouda, Rachel Darnell,
Olatunden Macaulay, Lucy Freeman, William Dunsmuir. St Peters
Hospital, Chertsey, UK.
Aims: BAUS and NICE guidelines recommend non-contrast CTKUB for
diagnosing renal calculi. This is not always possible in district general
hospitals, particularly out-of-hours. We audited imaging of suspected
renal colic in a DGH.
Methods: Prospective audit of 61 patients with suspected renal colic. Data
collected included initial and subsequent imaging and delays to deﬁnitive
management.
Results: CTKUB was ﬁrst-line imaging in 26 patients (42.6%), intravenous
urogram (IVU) in 19 (31.1%), ultrasound scan in 11 (18%), and plain
abdominal x-ray in 5 (8.2%). Of those investigated with IVU initially, 84%
were performed outside of working hours (0900-1700). 40% of patients
who did not have an initial CTKUB subsequently required this for deﬁnitive
diagnosis. Mean delay between initial and subsequent imaging was >19
hours resulting in an extra night hospital stay for 9 patients, with
approximate additional cost to the trust of £4,500.
Conclusions: CTKUB has a better speciﬁcity and sensitivity than
IVU for diagnosing renal calculi. Unless clinically unwell, we recom-
mend CTKUB as ﬁrst-line in all cases of suspected renal colic, withplanned re-attendance for deﬁnitive imaging if presenting out-of-hours.
This should reduce additional radiation to patients, reduce delays in
management and discharge, and provide additional cost-savings to
the trust.
1211: BARRIERS TO DECISION MAKING IN CANCER MULTIDISCIPLINARY
TEAMS. ANALYSIS OF CANCER DECISION-MAKING IN TWO SURGICAL
SPECIALITIES
Rozh Jalil 1, Marcelo Vasquez Rios 2, Nick Sevdalis 1, James Green 2.
1 Imperial College London, London, UK; 2Barts Health NHS Trust, London, UK.
Introduction: In the UK, the multidisciplinary setting has become the
standard to discuss cancer cases, yet there is no agreed way to assess the
efﬁcacy of MDT meetings (MDMs). This study investigated the factors
hampering decision-making in cancer MDMs.
Methods: All available MDT decision outcomes of cancer patients dis-
cussed between February to December 2012 of both Urology and colorectal
surgery were reviewed. MDT decisions and reasons for cases with no de-
cision reached were analysed.
Results:MDT discussion outcome of 2035 cancer cases were reviewed (19
Urology MDMs, n¼1126, 50 Colorectal MDMs, n¼909). 9.5%(n¼107) of
Urology and 6.4%(n¼58) of colorectal cases had no decision reached. Main
reasons were: unavailability of histopathological results (47.7%(n¼51) of
urology and 24.1%(n¼14) of Colorectal cases); unavailability of radiological
investigation results (43.9%(n¼47) of Urology and 43.1%(n¼25) of Colo-
rectal cases); unavailability of an Oncologist in the meeting(3.7%(n¼4) of
Urology and 5.2%(n¼3) of Colorectal cases).
Discussion: This study uncovers the main barriers that MDTs face in de-
cision-making. Assessing the efﬁcacy of a MDT could be made by its
capability to formulate a decision plan for all the cases discussed. Tackling
these barriers would result in a more cost-effective process, enhance de-
cision-making and thus enhance cancer care.
1245: SURGICAL AND ONCOLOGICAL OUTCOMES FOLLOWING NEPH-
ROURETERECTOMY IN THE MANAGEMENT OF UTTCC
Anna Mainwaring, Adam Carter, Daniel Painter. Royal Gwent Hospital,
Newport, UK.
Aim: The oncological behaviour of upper urinary tract transitional cell
carcinomas UTTCC is varied but more advanced disease is notoriously
aggressive. We reviewed the surgical and oncological outcomes following
open (ONU) and laparoscopic nephro-ureterectomy (LNU) in the treatment
of UTTCC at our institution.
Methods: Medical records and departmental databases of patients un-
dergoing NU between 2004 and 2011 were reviewed. Complications were
recorded using the Clavien-Dindo classiﬁcation.
Results: Sixty one patients with a minimum follow up of 12 months were
included (median age 71 years). Fifty six (92%) patients had LNU. Thirteen
patients (21%) had post-operative complications - 8 were Grade 1 and 5
were Grade 2. Histology conﬁrmed 53 (87%) TCC tumours and 1 (1.5%) case
had inoperable UTTCC disease. At median follow up of 32 months, 17 (32%)
patients developed de-novo bladder TCC and 7 (13%) systemic recurrence.
Overall and disease speciﬁc survival was 67% and 88% respectively. Despite
34 of 54 patients (63%) having G3 or T2 disease, only 5 (9%) died of
disseminated TCC and 13 (24%) died of other causes.
Conclusion: Our data is consistent with other similar large series' in the
literature. Most deaths observed during follow-up were from competing
causes rather than recurrent UTTCC.
1246: PAIN RELATED AND OVERALL MORBIDITY WITH TRUS GUIDED
PROSTATE BIOPSY e A PROSPECTIVE STUDY
Sarvpreet Ubee, Rajendra Marri, Shalom Srirangam. East Lancashire
Hospitals NHS Trust, Blackburm, UK.
Introduction: Assess analgesia requirement after trans-rectal ultrasound
guided prostate biopsy (TRUSBx) for appropriate counselling.
Materials and Methods: Prospectively, successive patients undergoing
TRUSBx ﬁlled questionnaires. Sextant TRUSBx under peri-prostatic block
(1% lidocaine) and antibiotic prophylaxis were performed. Pain perception
was assessed using a Visual Analogue Score (VAS).
Results: Mean age of 405 patients was 67.5 years. Mean VAS during the
procedure was 2.93 and 2.20 on reaching home. Mean maximum VAS for
the cohort on day 1 and day 2 were 1.27 and 0.7 respectively. 140 (35%)
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ABSTRACTSwere independent with some or minimal discomfort. 14 patients required
assistance for some of their basic daily needs. 9 patients (2.2%) had sepsis.
131 patients (32.4%) required additional oral analgesia following TRUSBx
on days 0, 1 and 2. Mean age of these patients was 63.6 years. This group
had mean VAS during the procedure of 4 and when patients reached home
was 3.5. Mean maximum VAS on day 1 and 2 was 2.1 and 1.3 respectively.
Conclusion: A third of patients require self-medicated analgesia post-
procedure. Age alone cannot be used as a criterion to identify patients who
will subsequently require analgesia post-procedure, but a higher VAS
during the procedure may be indicative.
1304: CHAIRING AND LEADERSHIP IN MULTIDISCIPLINARY CANCER
TEAMS: DEVELOPMENT AND EVALUATION OF AN ASSESSMENT TOOL
Rozh Jalil 1, Waseem Akhter 2, James Green 2, Nick Sevdalis 1. 1 Imperial
College London, London, UK; 2Barts Health NHS Trust, London, UK.
Introduction: High quality leadership and chairing skills are vital for good
performance in cancer multidisciplinary teams(MDTs), but no tools exist
for assessment. Our objective was to construct a robust tool for assessment
of MDT-chairing performance.
Methods: An observational tool was developed to assess the chairing and
leadership skills of MDT chair. The tool includes 11 elements of effective
MDT chairing. After it was content-validated by 10 senior MDT members,
theMDTchair personwas assessed by two surgeons(blinded to each other)
in seven live-observed Urology MDT meetings (286 cases) and ten video
recorded MDTs(131 cases) of different specialities. All chairing elements
were analysed via descriptive statistics. Intraclass correlation coef-
ﬁcients(ICCs) were used to assess inter-rater agreement and assessors'
learning curves.
Results: The inter-rater agreement was adequate-high(ICC¼ 0.63-0.91) for
all of the chairing elements. Agreement was higher in live MDT rat-
ings(mean 0.79,SD 0.092) compared to video ratings(mean 0.72,SD 0.069).
Conclusion: an observational assessment tool can be reliably used for
assessing the chair person in cancer MDTs (both in live and video-recor-
ded). Such robust assessment tools provide part of a toolkit for MDT
leadership evaluation and enhancement. The ability to feed back their
performance to MDT leads can enable promotion of good practice.
1308: HYPERTHERMIC MITOMYCIN C IN THE TREATMENT OF HIGH RISK
NON MUSCLE INVASIVE BLADDER CANCER e IS IT EFFECTIVE AND
SAFE? A REGIONAL CENTRE'S EXPERIENCE
Tsong Kwong, Anand Tana, Ben Ayres, Matthew Perry, Mike Bailey,
Rami Issa. St George's Hospital, London, UK.
Aims: High risk non muscle invasive bladder cancer (HRNMIBC) is
commonly treated with intravesical BCG, but fails in approximately 50% of
patients after 5 years. Hyperthermic Mitomycin C (HTMMC) is now being
considered for patients who failed BCG and avoid cystectomy. Our pro-
spective study was to investigate efﬁcacy and tolerance of HTMMC and
factors that inﬂuence success.
Methods: Patients with HRNMIBC who failed BCG or are immunocom-
promised were treated with HTMMC from June 2006 to June 2012. In-
duction HTMMC was given at 42+/-2oC through a Synergo device, with
induction and regular maintenance courses. Every three months, cystos-
copy and cytology was taken.
Results: Of 95 eligible patients, 75 completed at least one review. 77% of
patients had a complete response with HTMMC. High grade cancer and CIS
did not inﬂuence HTMMC initial response. No Clavien score over 2 was
reported. Median follow up was 33 (3-78) months. At 5 years, disease
speciﬁc survival was 96.8%, overall survival was 82.3% and failure-free
survival was 47.6%. 14 proceeded to cystectomy on HTMMC failure, with 11
performed locally. Of the 11, all had organ-conﬁned disease.
Conclusion: HTMMC is well tolerated and suitable treatment for patients
who are unﬁt or do not wish cystectomy.
1317: THE USE OF STAGING AND MULTIPARAMETRIC MRI IN PROSTATE
CANCER e A NATIONAL SURVEY
Sophia Cashman, Evangelos Gkougkousis, Paula Allchorne, Bruce Turner,
James S.A. Green. Barts Health NHS Trust, London, UK.
Introduction: Current guidelines on the use of multiparametric MRI in
prostate cancer are limited. Its role indiagnosing and stagingprostate cancer
remains a subject of debate. We designed a questionnaire to assess thecurrent uptake of both staging MRI prior to treatment decision, and the use
of multiparametric MRI prior to initial prostate biopsy in target patients.
Methods: Questionnaires were handed out to healthcare professionals
involved with uro-oncology MDTs. Individuals at each of the urology
specialist multi-disciplinary team (SMDT) centres in England were also
contacted by email, with a link to the questionnaire.
Results: In total, 79 responses from 57 centres were received. Of these, 46
centres reported having a protocol which deﬁnes which patients have a
staging MRI prior to treatment decision. Nine centres report using multi-
parametric MRI prior to initial biopsy in target patient, which includes
centres using this as part of a research trial or service improvement
assessment.
Discussion: Our data suggests that the use of multiparametric MRI as an
imaging modality is limited. This is in keeping with the current limited
data on its value as a diagnostic tool. Further evidence is needed to assess
its role within the diagnostic pathway for prostate cancer.
1345: RADIATION EXPOSURE IN UROLOGICAL SURGERY: AN AUDIT OF
CLINICAL PRACTICE
Jennifer Martin, Paul Downey, Binu Thomas. Causeway Hospital, Coleraine,
Northern Ireland, UK.
Aim: Intraoperative radiology has led to an evolving awareness of the
potential risks of radiation exposure. The increased use of radiation within
urology necessitates further study and this audit evaluated its use in
comparison to guidelines produced by the IAEA (International Atomic
Energy Agency).
Methods: From January to September 2012, 176 patients were identiﬁed
from a retrospective review of theatre records, to have undergone one of
ﬁve types of urology surgery involving radiation exposure. Procedure type,
screening time and radiation dose area product were recorded, fromwhich
the effective radiation dose was calculated. Performance was reviewed and
compared against IAEA guidelines.
Results: All ﬁve procedures were found to have used lower levels of ra-
diation in comparison to the IAEA guidelines. Variations in radiation doses
between individual urologists were identiﬁed, with a particularly wide
effective radiation dose range of 0.8mSv to 1.9mSv found in the com-
monest procedure, ureteroscopy and laser lithotripsy.
Conclusions: Intra-operative radiation use at Causeway Hospital appears
to be well below the levels recommended by the IAEA. Measures to
continue to effectively treat urological disease whilst minimising patient
radiation exposure should be introduced.
1367: CAN TRANSPERINEAL SECTOR BIOPSY PREDICT FINAL PATHOL-
OGY MORE ACCURATELY THAN TRUS BIOPSY OR MRI?
David Eldred-Evans, Paul Sturch, Janette Kinsella, Prokar Dasgupta,
Rick Popert, Declan Cahill, Ben Challacombe. Guys and St. Thomas’
Hospital, London, UK.
Objectives: To compare the accuracy of TRUS biopsy, Transperineal sector
biopsy and multiparametric MRI (mp-MRI) at predicting ﬁnal pathology at
radical prostatectomy.
Methods: A retrospective diagnostic accuracy study of patients who all
had a mp-MRI, a TRUS biopsy and a transperineal sector biopsy followed
by a robot assisted radical prostatectomy (RARP) at a single institution
between January 2010 and December 2012. The ﬁnal pathology at radical
prostatectomy was compared across MRI, TRUS and TPSP.
Results: 104 consecutive patients were identiﬁed with a mean age 62
years (range 40-74) and a median PSA 7.9mg/L (range 0.8-40). The Gleason
score at radical prostatectomy was accurate in 71% transperineal sector
biopsies but only 27% TRUS biopsies. The Gleason score was upgraded in
77% TRUS biopsies compared to 16% transperineal sector biopsies.
There were 23 patients who had extracapsular extension (ECE) at radical
prostatectomy but only 25% were predicted by mp-MRI. The MRI did not
identify 12 patients staged at T3a and 4 patients staged at T3b.
Conclusions: Transperineal sector biopsy was the best predictor of ﬁnal
pathology. Neither TRUS biopsy nor MRI stage predicted ﬁnal pathology
reliably, particularly with regard to extracapsular extension, and this has
implications for the use of preoperative nomograms.
